ReviewSAGE open medicine2022
Aromatase inhibitor-associated musculoskeletal pain: An overview of pathophysiology and treatment modalities.
Review in SAGE open medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Aerobic exercise and aromatase inhibitor-associated musculoskeletal symptoms: results of a randomized clinical trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Trial
- Evaluating the Implementation Fidelity of the REJOIN (Using Exercise to Relieve Joint Pain and Improve Aromatase Inhibitor Adherence in Older Breast Cancer Survivors) Pilot Trial.Journal of applied gerontology : the official journal of the Southern Gerontological Society · 2026Article
- Management Strategies for Aromatase Inhibitor-Associated Musculoskeletal Symptoms and Their Impact on Treatment Persistence in Postmenopausal Breast Cancer: A Single-Center Retrospective Cohort Study.International journal of women's health · 2026Article
- Arnica/Levisticum 6x comp. can alleviate musculoskeletal symptoms in breast cancer patients undergoing endocrine therapy: a case series.Frontiers in oncology · 2026Article
- Effect of Androgens on Human Fascia.Biology · 2025Article
- Determination and Disposition of the Aromatase Inhibitor Exemestane in CYP3A-Deficient Mice.Molecules (Basel, Switzerland) · 2025Article
- OATP1B-type Transport Function Is a Determinant of Aromatase Inhibitor-Associated Arthralgia Susceptibility.Cancer research communications · 2025Article
- Musculoskeletal symptoms associated with aromatase inhibitors in the treatment of early breast cancer: A scoping review of risk factors and outcomes.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Treatment Modalities for Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS): A Scoping Review of Prospective Treatment Studies.Journal of pain research · 2025Review
- Effects of the efficacy of theFrontiers in pharmacology · 2025Article
- The role of exercise in aromatase inhibitor-induced arthralgia.PM & R : the journal of injury, function, and rehabilitation · 2024Review
- Sticking to the script: Breast cancer patients' decision making regarding oral endocrine therapy.Patient education and counseling · 2024Article
- Real-world impact of acupuncture on analgesics and healthcare resource utilization in breast cancer survivors with pain.BMC medicine · 2024Article
- Article
- Health-Related quality of life by 31-item Cervantes scale in breast cancer survivors undergoing adjuvant endocrine therapy.Clinics (Sao Paulo, Brazil) · 2024Article
- A Recent Review of the Management of Postmenopausal Symptoms in Breast Cancer Survivors.Journal of menopausal medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since their introduction into clinical use in the 1970s, aromatase inhibitors have been a cornerstone of therapy for estrogen-receptor positive breast cancer in postmenopausal women. Unfortunately, this therapy leads to estrogen depletion in the body, which can lead to unpleasant side effects such as menopausal symptoms like hot flashes, insomnia, slightly increased risk of ischemic heart disease, accelerated bone loss leading to higher osteoporosis risk, and most significantly, arthralgias. The joint pain induced by aromatase inhibitor therapy is frequently cited as the leading cause of premature discontinuation; approximately 50% of patients will report new onset or worsening joint pain 1 year after therapy initiation, approximately 30% of patients discontinue therapy after 1 year, and only 50%-68% of patients remain fully compliant with therapy after 3 years. This article will describe risk factors for aromatase inhibitor-associated musculoskeletal syndrome, including genetic predispositions correlated with an increased risk of this syndrome, explain the currently understood pathophysiology, and give an overview of effective treatment options in managing this syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.